Study Dismisses Concerns that Psoriasis Treatment Could Trigger IBD

Study Dismisses Concerns that Psoriasis Treatment Could Trigger IBD
Taltz (ixekizumab), an approved antibody treatment for plaque psoriasis, targets a cytokine that is thought to play a role in the development of inflammatory bowel disease (IBD). That connection has caused concerns that administration of the drug might increase occurrence of IBDs in patients with psoriasis. So, Eli Lilly and Company, the maker of Taltz, conducted a

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

3 comments

  1. Linda Brewer says:

    Dismissal is a joke. I never had a single episode with IBD until I took Taltz. Now I’m waiting to see a GI doctor for a diagnosis. I took a total of 2 doses last September and still suffering from gastro problems. Taltz is poison!

    • Josh says:

      This can not be serious. I’ve never had gastro problems until I was using Taltz. After 2 months, I was diagnosed with Crohns and a rectal abscess formed which hospitalized me for 18 days. My life will never be the same thanks to Taltz and Lilly. The drug creator conducted this study – just let that sink in.

Leave a Comment

Your email address will not be published. Required fields are marked *